Valuation: BELLUS Health

Market Cap 1.86B 1.62B 1.52B 1.39B 2.62B 178B 2.65B 17.73B 6.96B 88.76B 7B 6.85B 295B P/E 2021
-8.95x
P/E 2022 -12.4x
Enterprise Value 1.53B 1.33B 1.24B 1.14B 2.15B 146B 2.17B 14.54B 5.7B 72.78B 5.74B 5.62B 242B EV / Sales 2021
36,416x
EV / Sales 2022 43,771x
Free-Float
81.52%
Yield 2021 *
-
Yield 2022 -
5 years 3.69
Extreme 3.69
19.9
10 years 0.76
Extreme 0.756
19.9
Manager TitleAgeSince
President - 01/06/2023
Director of Finance/CFO 53 07/12/2020
Chief Tech/Sci/R&D Officer 69 01/01/2010
Director TitleAgeSince
Chairman 79 01/01/2002
Director/Board Member 54 01/06/2009
Director/Board Member 80 01/06/2009
Date Insider Type Main position Quantity % Market Cap.
6/29/23 A OtherCompany 0 0%
6/22/23 A Option

Director

27,777 0.0219%
6/22/23 A Option

Executive/Senior Manager

75,000 0.0593%
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%-.--%-.--%-.--% 1.87B
-3.25%+13.72%+52.49%+88.86% 62.92B
+2.26%+3.46%+33.87%+74.35% 54.32B
-1.07%-1.79%-18.07%-14.36% 22.91B
+33.86%+30.60%+19.14%+502.77% 28.73B
+10.83%+18.38%+52.76%+4.58% 21.65B
+8.10%+8.74%+39.72%-20.46% 17.76B
-3.37%+25.85%+213.21%+369.13% 16.47B
+6.20%+11.51%+34.94%+681.88% 15.48B
-7.94%-6.74%+38.42%+157.52% 13.12B
Average +1.33%+7.31%+46.65%+184.43% 25.52B
Weighted average by Cap. +1.01%+8.55%+45.78%+165.28%

Financials

2021 2022
Net sales 16K 13.88K 13K 11.89K 22.45K 1.52M 22.75K 152K 59.69K 762K 60.07K 58.77K 2.53M 16K 13.88K 13K 11.89K 22.45K 1.52M 22.75K 152K 59.69K 762K 60.07K 58.77K 2.53M
Net income -71.22M -61.81M -57.88M -52.94M -99.95M -6.78B -101M -677M -266M -3.39B -267M -262M -11.28B -76.08M -66.02M -61.82M -56.55M -107M -7.25B -108M -723M -284M -3.62B -286M -279M -12.05B
Net Debt -248M -215M -201M -184M -348M -23.62B -352M -2.36B -925M -11.8B -931M -911M -39.28B -336M -291M -273M -250M -471M -31.99B -477M -3.19B -1.25B -15.98B -1.26B -1.23B -53.19B
Logo BELLUS Health
BELLUS Health Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (RCC). Camlipixant is a highly selective antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. It is being evaluated in the CALM phase III clinical development programmed. It is developing camlipixant for the treatment of adults with RCC. Camlipixant has the potential to address the significant unmet need for an efficacious, safe and well tolerated treatment for refractory chronic cough.
Employees
74